Ischemic optic neuropathies

Abstract

Application of the studies described in this paper should allow the clinician to more accurately diagnose ischemic optic neuropathies and counsel the patient with regard to appropriate management, prognosis for visual recovery and future risk of recurrence.

Etiological profile of presumptive optic neuritis in China

“…In addition, because poor visual outcome does not necessarily rule out the diagnosis of IDON After LHON, ischemic optic neuropathy (ION) is the second commonest disorder mimicking optic neuropathy in our group. There are many overlapping clinical features between ION and ON and in some patients it can be very difficult to distinguish between these two diagonoses 21,22 . Some researchers have suggested that there is an overlap of the mechanism of pathogenesis, making it difficult to distinguish with certainty between an "inflammatory" and "ischemic" etiology of optic neuropathy in certain caese 23 .…”

Changes in light sensitivity of the visual system with age and in patients with ischemic optic neuropathy

“…Дополнительными аргументами в пользу того, что на-рушение гемодинамики в сетчатке и других структурах зри-тельной системы является ведущей причиной снижения зрительных функций, являются описанные многими авто-рами снижение СОЗ различной степени, снижение кон-трастной чувствительности, ограничения и дефекты полей зрения при острой и хронической ИОН [4,35], сахарном диабете [36], глаукоме [37] и других заболеваниях [38][39][40][41][42].…”

Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction

“…14 The nonarteritic variant (NAION) has an annual incidence of 2.3-10.2 per 100 000 adults aged over 50 years in the United States. 15,16 It typically produces a rapid onset of painless monocular visual loss that worsens over hours to days, with associated optic disk edema that can be hyperemic (Figure 1c) or pallid, 17 and a relative afferent pupillary defect.…”

“…14 In a multicenter randomized trial, optic nerve sheath decompression was found to be ineffective and possibly harmful. 24 Although there is no proven prophylactic therapy to prevent NAION, most authors advocate control of vascular risk factors and the use of antiplatelet therapy, as there is about a 15% chance of recurrence in the fellow eye in the first 5 years following the initial presentation.…”

“…Differentiation of AAION from NAION is crucial, as the patient with AAION may go on to develop severe visual loss on the other side if corticosteroid therapy is not commenced in a timely fashion. 14 …”